BETA
Your AI-Trained Oncology Knowledge Connection!
Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.
Stay up to date on practice-changing data in community practice.
Real-World Study Shows Differences in Efficacy Among CDK4/6 Inhibitors for Advanced Breast Cancer
The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Considering How TAILORx Transformed Node-Negative Breast Cancer Treatment
During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
Yan Emphasizes Use of Supportive Care With Dato-DXd in Breast Cancer
During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.
Exploring Genomic Assays for Early-Stage Breast Cancer Treatment
During a live event, Heather L. McArthur, MD, MPH, reviewed genomic assays for early-stage breast cancer.